Shopping Cart
- Remove All
- Your shopping cart is currently empty
ET Receptor Antagonist 1 (compound 16h), with an IC50 value of 0.18 nM, is an orally active agent that can be utilized for pulmonary arterial hypertension (PAH) research. It has demonstrated efficacy in mitigating monocrotaline-induced PAH in a rat model [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder | |
50 mg | Inquiry | Backorder |
Description | ET Receptor Antagonist 1 (compound 16h), with an IC50 value of 0.18 nM, is an orally active agent that can be utilized for pulmonary arterial hypertension (PAH) research. It has demonstrated efficacy in mitigating monocrotaline-induced PAH in a rat model [1]. |
In vivo | ET receptor antagonist 1 (compound 16h), administered orally at 150 mg/kg/d and 300 mg/kg/d starting 48 hours post-MCT treatment for 21-26 days, significantly reduced mean pulmonary arterial pressure (mPAP) in MCT-exposed rats, decreased HIF1α, ANP, and TNNI3 levels, and exhibited antioxidant properties while inhibiting lipid peroxidation [1]. |
Molecular Weight | 459.52 |
Formula | C21H25N5O5S |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.